Bristol Myers Squibb is presenting 56-week phase 3 data in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) for camzius (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Meetings. shared.